Showing results (61-70 of 325) with videos related to

Sort By:
Pageof 33
The Medical Clinics of North America|July 1, 1998
Antithrombin agents as anticoagulants and antithrombotics. Implications in drug developmentJ Fareed, D Callas, D A Hoppensteadt, et al.
Haemostasis|January 1, 1991
Laboratory assays for the evaluation of recombinant hirudinJ M Walenga, D Hoppensteadt, M Koza, et al.
Nouvelle Revue Francaise D'Hematologie|January 1, 1984
Antithrombotic actions and pharmacokinetics of heparin fractions and fragmentsJ Fareed, A Kumar, J M Walenga, et al.
Seminars in Thrombosis and Hemostasis|October 1, 1983
Impact of automation on the quantitation of low molecular weight markers of hemostatic defectsJ Fareed, J M Walenga, R L Bick, et al.
International Angiology : a Journal of the International Union of Angiology|December 11, 2012
Thromboelastographic evaluation of blood coagulation in the presence of branded and generic enoxaparinsJ M Walenga, W P Jeske, V Escalante, et al.
Thrombosis Research|July 15, 1997
In vitro studies on the effect of activated protein C on platelet activation and thrombin generationB Kaiser, W Jeske, D H Hoppensteadt, et al.
Seminars in Thrombosis and Hemostasis|April 1, 1985
Usefulness of fibrinopeptide A generation tests in experimental and clinical studies with low molecular weight heparin fractionsR M Emanuele, J Fareed, J M Walenga, et al.
Thrombosis Research|October 29, 2000
Human anti-heparin-platelet factor 4 antibodies are capable of activating primate platelets: towards the development of a HIT model in primatesS Ahmad, W P Jeske, J M Walenga, et al.
Archives of Pathology & Laboratory Medicine|November 18, 2000
Pathophysiology of heparin-induced thrombocytopenia. Clinical and diagnostic implications--a reviewF Fabris, S Ahmad, G Cella, et al.
Haemostasis|January 1, 1988
Validity of the newly established low-molecular-weight heparin standard in cross-referencing low-molecular-weight heparinsJ Fareed, J M Walenga, A Racanelli, et al.
Pageof 33